DexCom, Inc.
DXCMHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, DexCom, Inc. (DXCM) is listed under Medical Devices. With a market capitalization of $29.58B, it sits in large-cap territory. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Market Cap
$29.58B
Beta
1.45
P/E (TTM)
33.47
P/E (Fwd)
24.91
EPS (TTM)
$2.29
EPS (Fwd)
$3.08
ROE
35.6%
ROA
9.7%
Cash
$2.42B
Total Debt
$1.38B
Free CF
$1.06B
52W Change
-8.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $2.42B in cash comfortably exceeding the $1.38B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $1.06B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 35.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.91B (2022) to $4.66B (2025), reflecting a 60% increase over the period.
Investors considering DexCom, Inc. should weigh the typical risks associated with DXCM's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DXCM.